FDA approves generic version of Vumerity for relapsing MS
by Patricia Inacio, PhD | November 18, 2025 Zydus capsules to be used for same indications as brand-name treatment Zydus Lifesciences received final approval…
Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar Basel, November 17, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the…
Stuart Schlossman
Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared…
Stuart Schlossman
video: Moderated & Public Q&A with MS Neurologists Boster and LaGanke
Event date: July 26, 2025 Moderator: Stuart Schlossman, President of MS Views and News / MS Patient Advocate At the…
Stuart Schlossman
Fumarates Lead to Lower Infection-Related Healthcare Resource Utilization Relative to Anti-CD20s
May 30, 2025 Key Takeaways A study reveals long-term fumarate therapy significantly reduces infection-related healthcare utilization in multiple sclerosis patients…
Stuart Schlossman
MS Therapy Cladribine Remains Effective in Patients With Suboptimal Response to Prior Injectable DMT
May 14, 2025 Cladribine shows promising results in reducing relapse rates for patients with relapsing multiple sclerosis after inadequate response…
Stuart Schlossman
Rebound Effect Not Observed With Multiple Sclerosis Therapy Ozanimod
Author: Marco Meglio – May 29, 2025 Key Takeaways A recent large cohort analysis of global MS registry data reported…
Stuart Schlossman
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Paris, April 8, 2025. The New…
Stuart Schlossman
Patient Experiences with the Impacts of Multiple Sclerosis & Disease-Modifying Therapies
Bari Talente,1 Lisbet T Finseth,1 Natalie Blake,2 Kathleen Costello,3 Hollie Schmidt,4 Joe Vandigo,5 Elisabeth M Oehrlein5 1National Multiple Sclerosis Society, Washington, DC, USA; 2Multiple Sclerosis Foundation, Fort…
Stuart Schlossman
ACTRIMS 2025: Tolebrutinib impact greater in MS patients with PRLs
Treatment candidate found effective in reducing disability progression risk by Andrea Lobo, PhD | March 5, 2025 — #ACTRIMS Sanofi’s experimental BTK inhibitor tolebrutinib is…
Stuart Schlossman
